Editorial for “Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells”
Author Contributions
Funding
Conflicts of Interest
References
- Furnari, F.B.; Fenton, T.; Bachoo, R.M.; Mukasa, A.; Stommel, J.M.; Stegh, A.; Hahn, W.C.; Ligon, K.L.; Louis, D.N.; Brennan, C.; et al. Malignant Astrocytic Glioma: Genetics, Biology, and Paths to Treatment. Genes Dev. 2007, 21, 2683–2710. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ostrom, Q.T.; Patil, N.; Cioffi, G.; Waite, K.; Kruchko, C.; Barnholtz-Sloan, J.S. CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013–2017. Neuro-Oncology 2020, 22, iv1–iv96. [Google Scholar] [CrossRef]
- Tang, D.G. Understanding Cancer Stem Cell Heterogeneity and Plasticity. Cell Res. 2012, 22, 457–472. [Google Scholar] [CrossRef] [Green Version]
- Seymour, T.; Nowak, A.; Kakulas, F. Targeting Aggressive Cancer Stem Cells in Glioblastoma. Front. Oncol. 2015, 5, 159. [Google Scholar] [CrossRef]
- Arora, A.; Somasundaram, K. Glioblastoma vs. Temozolomide: Can the Red Queen Race Be Won? Cancer Biol. Ther. 2019, 20, 1083–1090. [Google Scholar] [CrossRef]
- Alves, A.L.V.; Gomes, I.N.F.; Carloni, A.C.; Rosa, M.N.; Da Silva, L.S.; Evangelista, A.F.; Reis, R.M.; Silva, V.A.O. Role of Glioblastoma Stem Cells in Cancer Therapeutic Resistance: A Perspective on Antineoplastic Agents from Natural Sources and Chemical Derivatives. Stem Cell Res. Ther. 2021, 12, 206. [Google Scholar] [CrossRef] [PubMed]
- Hardee, M.E.; Zagzag, D. Mechanisms of Glioma-Associated Neovascularization. Am. J. Pathol. 2012, 181, 1126–1141. [Google Scholar] [CrossRef] [Green Version]
- Scully, S.; Francescone, R.; Faibish, M.; Bentley, B.; Taylor, S.L.; Oh, D.; Schapiro, R.; Moral, L.; Yan, W.; Shao, R. Transdifferentiation of Glioblastoma Stem-like Cells into Mural Cells Drives Vasculogenic Mimicry in Glioblastomas. J. Neurosci. Off. J. Soc. Neurosci. 2012, 32, 12950–12960. [Google Scholar] [CrossRef] [Green Version]
- Ricci-Vitiani, L.; Pallini, R.; Biffoni, M.; Todaro, M.; Invernici, G.; Cenci, T.; Maira, G.; Parati, E.A.; Stassi, G.; Larocca, L.M.; et al. Tumour Vascularization via Endothelial Differentiation of Glioblastoma Stem-like Cells. Nature 2010, 468, 824–828. [Google Scholar] [CrossRef]
- El Atat, O.; Naser, R.; Abdelkhalek, M.; Habib, R.; El Sibai, M. Molecular Targeted Therapy: A New Avenue in Glioblastoma Treatment (Review). Oncol. Lett. 2022, 25, 46. [Google Scholar] [CrossRef] [PubMed]
- Brar, H.K.; Jose, J.; Wu, Z.; Sharma, M. Tyrosine Kinase Inhibitors for Glioblastoma Multiforme: Challenges and Opportunities for Drug Delivery. Pharmaceutics 2022, 15, 59. [Google Scholar] [CrossRef] [PubMed]
- Tilak, M.; Holborn, J.; New, L.A.; Lalonde, J.; Jones, N. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme. Int. J. Mol. Sci. 2021, 22, 1831. [Google Scholar] [CrossRef] [PubMed]
- Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J.M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; et al. Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N. Engl. J. Med. 2001, 344, 1031–1037. [Google Scholar] [CrossRef] [Green Version]
- Huang, L.; Jiang, S.; Shi, Y. Tyrosine Kinase Inhibitors for Solid Tumors in the Past 20 Years (2001–2020). J. Hematol. Oncol. 2020, 13, 143. [Google Scholar] [CrossRef]
- Grothey, A.; Blay, J.-Y.; Pavlakis, N.; Yoshino, T.; Bruix, J. Evolving Role of Regorafenib for the Treatment of Advanced Cancers. Cancer Treat. Rev. 2020, 86, 101993. [Google Scholar] [CrossRef] [Green Version]
- Daudigeos-Dubus, E.; Le Dret, L.; Lanvers-Kaminsky, C.; Bawa, O.; Opolon, P.; Vievard, A.; Villa, I.; Pagès, M.; Bosq, J.; Vassal, G.; et al. Regorafenib: Antitumor Activity upon Mono and Combination Therapy in Preclinical Pediatric Malignancy Models. PLoS ONE 2015, 10, e0142612. [Google Scholar] [CrossRef]
- Deshors, P.; Arnauduc, F.; Boëlle, B.; Cohen-Jonathan Moyal, E.; Courtade-Saïdi, M.; Evrard, S.M. Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells. Cancers 2022, 14, 1551. [Google Scholar] [CrossRef]
- De Pascalis, I.; Morgante, L.; Pacioni, S.; D’Alessandris, Q.G.; Giannetti, S.; Martini, M.; Ricci-Vitiani, L.; Malinverno, M.; Dejana, E.; Larocca, L.M.; et al. Endothelial Trans-Differentiation in Glioblastoma Recurring after Radiotherapy. Mod. Pathol. 2018, 31, 1361–1366. [Google Scholar] [CrossRef] [Green Version]
- Deshors, P.; Toulas, C.; Arnauduc, F.; Malric, L.; Siegfried, A.; Nicaise, Y.; Lemarié, A.; Larrieu, D.; Tosolini, M.; Cohen-Jonathan Moyal, E.; et al. Ionizing Radiation Induces Endothelial Transdifferentiation of Glioblastoma Stem-like Cells through the Tie2 Signaling Pathway. Cell Death Dis. 2019, 10, 816. [Google Scholar] [CrossRef] [Green Version]
- Lombardi, G.; De Salvo, G.L.; Brandes, A.A.; Eoli, M.; Rudà, R.; Faedi, M.; Lolli, I.; Pace, A.; Daniele, B.; Pasqualetti, F.; et al. Regorafenib Compared with Lomustine in Patients with Relapsed Glioblastoma (REGOMA): A Multicentre, Open-Label, Randomised, Controlled, Phase 2 Trial. Lancet Oncol. 2019, 20, 110–119. [Google Scholar] [CrossRef] [PubMed]
- Da Ros, M.; De Gregorio, V.; Iorio, A.; Giunti, L.; Guidi, M.; De Martino, M.; Genitori, L.; Sardi, I. Glioblastoma Chemoresistance: The Double Play by Microenvironment and Blood-Brain Barrier. Int. J. Mol. Sci. 2018, 19, 2879. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zeiner, P.S.; Kinzig, M.; Divé, I.; Maurer, G.D.; Filipski, F.; Harter, P.N.; Senft, C.; Bähr, O.; Hattingen, E.; Steinbach, J.P.; et al. Regorafenib CSF Penetration, Efficacy, and MRI Patterns in Recurrent Malignant Glioma Patients. J. Clin. Med. 2019, 8, 2031. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Guntner, A.S.; Peyrl, A.; Mayr, L.; Englinger, B.; Berger, W.; Slavc, I.; Buchberger, W.; Gojo, J. Cerebrospinal Fluid Penetration of Targeted Therapeutics in Pediatric Brain Tumor Patients. Acta Neuropathol. Commun. 2020, 8, 78. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kolothara Unnikrishnan, M.; Schmidt, M.H.H. Editorial for “Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells”. Cancers 2023, 15, 3830. https://doi.org/10.3390/cancers15153830
Kolothara Unnikrishnan M, Schmidt MHH. Editorial for “Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells”. Cancers. 2023; 15(15):3830. https://doi.org/10.3390/cancers15153830
Chicago/Turabian StyleKolothara Unnikrishnan, Madhukrishna, and Mirko H. H. Schmidt. 2023. "Editorial for “Impact of Regorafenib on Endothelial Transdifferentiation of Glioblastoma Stem-like Cells”" Cancers 15, no. 15: 3830. https://doi.org/10.3390/cancers15153830